EAS 50th anniversary: Celebrate in Madrid 2014 with the latest in atherosclerosis research

About 2000 delegates from over 70 countries across five continents will converge on Madrid to help EAS mark this milestone. EAS Madrid 2014 is hosted by the Spanish Society of Arteriosclerosis.

The EAS was founded in 1964 with the mission to “advance and exchange knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease”. With atherosclerosis becoming an increasingly important concern as European populations grow older, the work of the Society is today more relevant than ever.

President of the EAS 2013-2017, Professor Alberico L. Catapano (University of Milan, Italy) highlights the importance of EAS turning 50:

‘Madrid 2014 is a special occasion as it marks the 50th Anniversary of EAS. Over this time, the Society has become a leading player in atherosclerosis research and education in Europe. EAS has been at the forefront of basic research into the mechanisms that underlie atherosclerosis, as well as clinical initiatives focused on discovery of new treatments and optimising the management of dyslipidaemia.

2014 heralds a very exciting time in lipids and atherosclerosis research. Recent discoveries in genetics and pharmacology have driven the development of novel therapies targeting atherosclerosis. Now, more than ever, EAS remains committed to improving patient care to reduce the burden of cardiovascular disease.’

Highlights of EAS Madrid 2014

Working with the host Spanish Society of Arteriosclerosis and Congress Chair, Prof. Jesús Millán Núñez-Cortés (Universitario Gregorio Marañón Catedrático de Medicina, Universidad Complutense), EAS Madrid 2014 offers an exciting programme spanning basic and clinical research.

‘The Spanish Society of Arteriosclerosis, under the Presidency of Her Majesty The Queen Sofia of Spain, welcomes all delegates to EAS Madrid. The Congress offers both cutting-edge atherosclerosis research and results from clinical trials, together with outstanding state of the art plenaries.’ - Prof. Jesús Millán Núñez-Cortés, EAS Madrid Congress Chair.
• **The Anitschkow Lecture**, given by this year’s recipient of the Anitschkow Prize, **Professor John J.P. Kastelein**, Professor of Medicine at the Department of Vascular Medicine, Academic Medical Center (AMC) of the University of Amsterdam and Strategic Chair of Genetics of Cardiovascular Disease. Professor Kastelein has been a leading proponent of the “extreme genetics” approach in research, in which the study of rare human disorders associated with premature coronary disease has had broader application in understanding the aetiology of heart disease, as well as identifying therapeutic targets that are valid for all patients. This approach has been successful in defining familial hypercholesterolaemia (FH) as the paradigm for the relationship between low-density lipoprotein cholesterol (LDL-C) and heart disease; as well as disorders of high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides. Such genetic insights have been instrumental in the development of gene therapy for lipoprotein lipase deficiency. Prof. Kastelein’s current research interests focus on the aetiology, diagnosis, prevention and treatment of hypertriglyceridaemia, hypercholesterolaemia and low HDL-C, all conditions associated with atherosclerosis and cardiovascular disease.

‘Professor John Kastelein has been at the forefront in translating insights from genetic studies to innovative therapeutic approaches’ – EAS President, Prof. Alberico L. Catapano.


The Anitschkow lecture will be a focus of the Opening Ceremony of EAS Madrid, Saturday May 31st, 18:00-19:30.

• **The Plenary Sessions**, an important feature of EAS Congresses, offer exciting state of the science lectures from leading international experts. Topics covered during EAS Madrid 2014 include:
  - The role of immunity in atherosclerosis, exploring the potential of vaccines and the microRNAs [Sunday June 1st, 08:30-10:30]
  - Cardiometabolic disease, including future prospects for non-alcoholic fatty liver disease [Monday 2nd June, 08:30-10:30]
  - Residual cardiovascular risk beyond statins, and the potential of emerging risk factors as contributors to this risk
  - PCSK9 inhibition: possibilities for targeting this residual risk [Tuesday 3rd June, 08:30-10:30]

‘These Plenary Sessions, with lectures by leading experts in these fields, provide an important educational resource and a timely update for EAS members’

– EAS President, Prof. Alberico L. Catapano
• **Late Breaking Sessions**: Building on the strength of previous Congresses, this year there will be two Late Breaking Sessions.
  - **Late Breaking Session I** highlights clinical trials with novel therapeutic approaches. Of particular interest will be presentation of data from the phase III trial with the PCSK9 monoclonal antibody evolocumab in homozygous FH (TESLA). *[Sunday June 1st, 15:45-16:30]*
  - **Late Breaking Session II** provides further information on the early stages of development of new therapies, including imaging trials; genetic insights; and long-term follow-up data with a novel gene therapy for lipoprotein lipase deficiency. *[Monday June 2nd, 15:45-16:30]*

In addition, **Workshops at EAS Madrid** offer new insights into exciting topics including:

- New targets for lipid-lowering therapy *[Sunday June 1st, 11:45-12:30]*
- Environmental and metabolic stressors in cardiovascular disease *[Monday June 2nd, 11:00-12:30]*
- Nutrition and nutraceuticals *[Monday June 2nd, 11:00-12:30]*
- Novel protective effects of HDL *[Monday June 2nd, 15:00-16:30]*
- Hypolipidaemic drugs, present and future *[Tuesday June 3rd, 11:00-12:30]*
- Optimising the treatment of FH *[Tuesday June 3rd, 11:45-12:30]*

**EAS: Building on links with other Societies**

Collaborations with societies focused on the prevention and treatment of cardiovascular disease, including the European Society of Cardiology (ESC) and the Society of Laboratory Medicine, as well as local societies throughout Europe and beyond, have the common aim of improving patient care. EAS Madrid showcases two joint sessions:

- **Joint Symposium with the ESC**: Lipid lowering in CVD prevention: where do we stand and where are we going? This Workshop will review current guidelines for dyslipidaemia management and cardiovascular disease prevention, and discuss the challenges for the future in terms of lipid and non-lipid targets. *[Sunday, June 1st, 15:00-16:30]*
- **Joint ICCR-EAS Workshop**: Targeting lifestyle in CVD risk management and prevention. This Workshop discusses the integral role of lifestyle in cardiovascular disease prevention, with insights from the PREDIMED and LookAhead studies. *[Monday, June 2nd 15:00-16:30]*
EAS Initiatives: At the forefront for education

The European Atherosclerosis Society’s goal is to provide a framework for scientific and clinical discussion of new developments in basic research, diagnosis and therapy of atherosclerosis.

‘Fifty years on, the EAS continues to build on its strengths and address the needs of members. The Society has an even more relevant role in the area of guidelines for the management of dyslipidemia, and for global risk, as well as addressing specific areas of concern, driven by the Consensus Panel initiatives. The EAS is recognized as a trusted source of information by its members and by the scientific community’ - EAS President, Prof. Alberico L. Catapano.

Initiatives Update Session: EAS President, Prof. Alberico L. Catapano (University of Milan, Italy) and Vice-President, Prof. Olov Wiklund (Sahlgrenska University Hospital, Gothenburg, Sweden), will discuss ongoing and new initiatives by the Society [Monday June 2nd, 15:00-16:30].

Ongoing EAS Initiatives

- **EAS Academy**: The Society’s on-line educational resource, with webcasts, podcasts, technical videos and learning tools, guidelines, consensus papers, and other educational resources under the responsibility of Professor S. Lale Tokgözoglu (Hacettepe University, Ankara, Turkey). Full access to the EAS Academy is one of the key benefits of Society membership. For further information: [http://www.eas-society.org/eas-academy.aspx](http://www.eas-society.org/eas-academy.aspx)

- **EAS Consensus Panel**: The EAS Consensus Panel has been one of the most successful initiatives of the Society. The Consensus Panel is co-chaired by Professor M. John Chapman, EAS Past-President (INSERM U939, Pitié-Salpetrière University Hospital, Paris, France) and Professor Henry N. Ginsberg (Columbia University, New York, USA). The EAS Consensus Panel has previously produced statements on:
  - Lipoprotein(a)
  - Triglyceride-rich lipoproteins and HDL-C
  - FH
  - Phytosterol-supplemented foods in dyslipidaemia management and cardiovascular disease prevention

Ongoing initiatives focus on homozygous FH and statin intolerance.

- **EAS Advanced Courses**: These courses highlight a different aspect of basic science and research or clinical prevention, diagnosis and treatment in the field of atherosclerotic vascular disease and its complications. The courses are run by recognised experts and distinguished specialists in the relevant research or clinical area.
EAS in the Future

The EAS is working very hard to further promote the growth of the Society and to ensure scientific excellence in meetings.

‘We believe that EAS Madrid reflects this goal. We continue to ensure that the EAS provides trustworthy, efficient and top-level education in atherosclerosis and cardiovascular disease. The Academy educational platform of the EAS, our journal Atherosclerosis, and the 2011 Joint ESC/EAS Guidelines are a clear example of this commitment.’ – EAS President, Professor Alberico L. Catapano

Contact:

<table>
<thead>
<tr>
<th>EAS Press Officer</th>
<th>EAS Administration Executive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Luis Masana</td>
<td>Dr. Carmel Hayes</td>
</tr>
<tr>
<td>+34610429554</td>
<td>+46 31 724 27 95 / +46768 61 00 51</td>
</tr>
<tr>
<td>Email: <a href="mailto:luis.masana@urv.cat">luis.masana@urv.cat</a></td>
<td>Email: <a href="mailto:office@eas-society.org">office@eas-society.org</a></td>
</tr>
</tbody>
</table>

Notes for editors:

About the European Atherosclerosis Society

The European Atherosclerosis Society represents nearly 1,000 basic scientists and clinicians. The mission of the EAS is to advance and exchange knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease.

Atherosclerosis is the process by which fatty deposits or plaques build up in blood vessels, eventually leading to heart attacks, strokes, intermittent claudication, and other diseases caused by chronically or acutely reduced blood flow. Already cardiovascular disease is the major cause of death and disability in Europe. As populations grow older, and as type 2 diabetes and obesity continue to escalate, atherosclerosis will become an increasingly important concern.

The Society’s main activities are focused on four main areas:

- The dissemination of up-to-date knowledge of the pathophysiology underlying atherogenic dyslipidemia and premature atherosclerosis
- The prevention, diagnosis and treatment of atherosclerotic vascular disease in non-diabetic and diabetic subjects
- The promotion of cutting-edge basic and clinical research in the field of atherosclerosis and related metabolic diseases such as Metabolic Syndrome and Type 2 Diabetes
• The support, promotion, and organization of scientific Congresses and Workshops both within and outside Europe on topics related to atherosclerosis in its widest sense. These include:
  - Lipid, lipoprotein and cholesterol metabolism
  - Vascular biology
  - Mechanisms underlying atherosclerosis and clinical cardiovascular events, particularly myocardial infarction
  - Cerebro- and peripheral vascular disease
  - Genetics of atherosclerotic vascular diseases
  - Plaque imaging modalities
  - Pharmacotherapy of lipid disorders
  - Prevention of atherosclerotic vascular disease

For further information refer to http://www.eas-society.org/home.aspx.

For information about Atherosclerosis, the journal of the EAS:
http://www.atherosclerosis-journal.com/

About the European Consensus Panel
The EAS Consensus Panel is comprised of internationally renowned experts in atherosclerosis and cardiovascular disease, and is co-chaired by Professor John Chapman (INSERM U939, Pitié-Salpetriere University Hospital, Paris, France) and Professor Henry Ginsberg (Columbia University, New York, USA). The Panel was first convened in November 2009 to consider the evidence for non-LDL lipids as risk factors for cardiovascular disease. Subsequent Consensus Panels have focused on familial hypercholesterolaemia, hypertriglyceridaemia, and the role of foods supplemented with plant sterols/stanols in dyslipidaemia management and cardiovascular disease prevention.

Recent publications:


Joint ESC/EAS Guidelines:


END